No headlines found.
ACCESS Newswire (Mon, 15-Dec 9:00 AM ET)
ACCESS Newswire (Wed, 10-Dec 9:00 AM ET)
Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream
Globe Newswire (Wed, 10-Dec 7:00 AM ET)
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Globe Newswire (Tue, 9-Dec 7:00 AM ET)
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
ACCESS Newswire (Mon, 8-Dec 4:15 PM ET)
ACCESS Newswire (Tue, 2-Dec 9:00 AM ET)
ACCESS Newswire (Mon, 24-Nov 9:00 AM ET)
ACCESS Newswire (Thu, 20-Nov 9:00 AM ET)
ACCESS Newswire (Mon, 17-Nov 8:00 AM ET)
ACCESS Newswire (Fri, 14-Nov 9:00 AM ET)
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Jaguar Health trades on the NASDAQ stock market under the symbol JAGX.
As of December 19, 2025, JAGX stock price climbed to $1.17 with 159,273 million shares trading.
JAGX has a beta of 2.68, meaning it tends to be more sensitive to market movements. JAGX has a correlation of 0.11 to the broad based SPY ETF.
JAGX has a market cap of $4.89 million. This is considered a Sub-Micro Cap stock.
Last quarter Jaguar Health reported $3 million in Revenue and -$6.28 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$2.02.
In the last 3 years, JAGX traded as high as $13,724.73 and as low as $1.00.
The top ETF exchange traded funds that JAGX belongs to (by Net Assets): VXF.
JAGX has underperformed the market in the last year with a return of -94.6%, while the SPY ETF gained +18.1%. In the last 3 month period, JAGX fell short of the market, returning -37.1%, while SPY returned +2.8%. However, in the most recent 2 weeks JAGX has outperformed the stock market by returning +8.3%, while SPY returned -0.5%.
JAGX support price is $1.03 and resistance is $1.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAGX shares will trade within this expected range on the day.
